Research and Development

Research and Development

Making Sawai first to market with high-value-added products and strengthening the system to continually offer new treatments to the U.S. market

Putting Our Whole Heart into Being First to Market with High-Value-Added Products

Putting Our Whole Heart into Being First to Market with High-Value-Added Products

While the Research & Development Division’s mission is to ensure Sawai is first to market with generic pharmaceuticals, we believe it is not enough to succeed in development alone. With a clear focus on avoiding infringement on patent rights for the original drug, our challenge is to develop high-value-added products and services that benefit a wide range of interested parties, including formulation and manufacturing methods optimal for managing costs and ensuring stable supply, labeling that helps avoid potential errors in medical treatment, and tablets that are easier to swallow.

Improving Our System for Submitting Applications for FDA Approval

In the wake of the FDA* approval of PITAVASTATIN Tablets, we are focused on strengthening our R&D system so that Sawai can submit at least one new treatment to the FDA each year for approval. Knowledge and experience gained in the U.S. approval process are accumulated and shared within the Company and actively utilized in on-the-job training. It also serves to advance the development of human resources that can be active in the Company’s global operations.
  • *FDA: U.S. Food and Drug Administration

Examples of Product Labelling for Tablets

CLOPIDOGREL tablets 25mg/50mg/75mg “Sawai” Methods used to make drugs easily identifiable include stamping the product name on both sides of the tablets and using universal fonts on the packaging sheets.

Number of Patents Held by Sawai

Number of Patents Held by Sawai
Operation
Products
Research and Development
Production Facilities
Other
Back to Top